Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

38 trials with published results (24%)

Research Maturity

101 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.5%

12 terminated out of 160 trials

Success Rate

89.4%

+2.8% vs benchmark

Late-Stage Pipeline

28%

44 trials in Phase 3/4

Results Transparency

38%

38 of 101 completed with results

Key Signals

38 with results89% success12 terminated

Data Visualizations

Phase Distribution

120Total
Not Applicable (46)
Early P 1 (1)
P 1 (11)
P 2 (18)
P 3 (27)
P 4 (17)

Trial Status

Completed101
Unknown16
Terminated12
Withdrawn10
Active Not Recruiting8
Recruiting7

Trial Success Rate

89.4%

Benchmark: 86.5%

Based on 101 completed trials

Clinical Trials (160)

Showing 20 of 20 trials
NCT05506423Active Not RecruitingPrimary

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

NCT06246136Not ApplicableRecruitingPrimary

Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery

NCT05269680Active Not RecruitingPrimary

STAR-LIFE: a Post-market Registry on MINIject

NCT04524416Active Not RecruitingPrimary

MINIject Global Long-Term Follow-up Study

NCT07619482Phase 1Not Yet RecruitingPrimary

Topical Insulin for Glaucoma (TING2)

NCT06666855Phase 3Active Not RecruitingPrimary

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

NCT07325240Phase 4RecruitingPrimary

24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients

NCT07082816Phase 3Completed

Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction

NCT06230393TerminatedPrimary

An Extension Trial for Patients With Open-Angle Glaucoma Who Participated in the DF6-CL-20-01 Protocol.

NCT05273385Not ApplicableTerminated

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT06851546Not ApplicableCompletedPrimary

Efficacy of Selective Laser Trabeculoplasty Targeting Nasal Versus Inferior 180-degree

NCT04060758Phase 1CompletedPrimary

Open Label, Sequential-dose Study of PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma

NCT06441643Phase 2CompletedPrimary

Next Generation Rocklatan

NCT07228221Phase 4RecruitingPrimary

Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma

NCT04630808Phase 3CompletedPrimary

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT05938699Phase 2CompletedPrimary

Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution

NCT03750201Not ApplicableCompletedPrimary

A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty

NCT04445519Phase 3CompletedPrimary

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT05035394Not ApplicableActive Not RecruitingPrimary

Swedish Microinvasive Glaucoma Surgery Study (SMIGS)

NCT06993311Completed

Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma

Scroll to load more

Research Network

Activity Timeline